Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

AIDS

Volumn 18, Issue 3, 2004, Pages 503-508

  Stephan, Christoph ^a   Hentig, Nils V ^a   Kourbeti, Irene ^a   Dauer, Brenda ^a   Mösch, Manfred ^a   Lutz, Thomas ^a   Klauke, Stephan ^a   Harder, Sebastian ^a   Kurowski, Michael ^b   Staszewski, Schlomo ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

Double boosted protease inhibitor; Lopinavir; Pharmacokinetics; Ritonavir; Saquinavir

Indexed keywords

LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; MEDICAL ASSESSMENT; PHOTOMETRY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEADY STATE; TANDEM MASS SPECTROMETRY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAPSULES; COHORT STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; SAQUINAVIR; VIRAL LOAD;

EID: 12144286333     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200402200-00017     Document Type: Article

References (24)

1. van Heeswijk RPG, Veldkamp AL, Mulder JW, Meenhorst PL, Lange JMA, Beijnen JH, et al. Combination of protease inhibitors for the treatment of HIV-1 infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2002, 6:201-229.
2. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001, 2:105-113.
3. Hsu A, Granneman RG, Bertz RJ. Ritonavir. clinical pharmacokinetics and interactions with other HIV agents. Clin Pharmacokinet 1998, 35:275-291.
4. Hammer SM, Vaida F, Bennett KK, Holothan MK, Sheiner L, Eron JJ, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure; ACTG 398 study team. JAMA 2002, 288:169-180.
5. Molla A, Mo H, Vasavanonda S, Han L, Lin CT, Hsu A, Kempf DJ. In vitro interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother 2002, 46:2249-2253.
6. Staszewski S, Dauer B, Stephan C, Kurowski M, Stürmer M, von Hentig N, et al. A new strategy: boosted double protease inhibitor regimen lopinavir/r plus saquinavir without reverse transcriptase inhibitors. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA, September 2002 [Abstract H-176].
7. Kurowski M, Müller M, Arasteh K, Moecklinghoff C. Simultaneous monitoring of five protease-inhibitors in HIV-infected patients by LC-tandem mass spectrometry. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA, September 1999 [Abstract 320]
8. Ackermann H. BIAS für Windows 95/98/ME/NT/2000/XP (version 7.06). Hochheim, Darmstadt: epsilon Verlag; 2002.
9. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002, 36:1193-1203.
10. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000, 14:1333-1339.
11. Hellinger J, Cohen CJ, Morris AB, Piscitelli S, Gordon D, Foy K, et al. Pilot study of the safety and antiviral activity of saquinavir 1000 mg twice daily and lopinavir/ritonavir (Kaletra) combination therapy in HIV positive individuals. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA, February 2002 [Abstract 451-W].
12. Ruiz L, Ribera E, Bonjoch A, Martinez-Picado J, Díaz M, Romeu J, et al. Virological and immunological benefit of a salvage therapy that includes Kaletra plus Fortovase preceded or not by antiretroviral therapy interruption (TI) in advanced HIV-infected patients (6-month-follow-up). In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA, February 2002 [Abstract 421-W].
13. Bertz RJ, Foit C, Ashbrenner E, Burt D, Williams LA, Chira T, et al. Assessment of the steady state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA, September 2002 [Abstract A-1822].
14. Zala C, Patterson P, Coll P, Bouzas MB, Kaufman S, Gun A, et al. Virological response and safety of double boosted protease inhibitors with lopinavir/r plus either saquinavir or amprenavir in heavily pretreated HIV infected patients. In: XIVth Internationa/ AIDS Conference. Barcelona, Spain, July 2002 [Abstract TuPeB4492].
15. Smith GHR, Klein MB, Murphy T, Gilmore N, Leblanc RP, Macleod J, et al. Double, boosted salvage therapy with lopinavir/ritonavir and saquinavir-sgc in HIV-1 infected patients having failed 3 classes of antiretrovirals. In: XIVth International AIDS Conference. Barcelona, Spain, July 2002 [Abstract TuPeB4547].
16. Klein C, Bertz R, Ashbrenner E, Chira T, Williams L, Hsu A, et al. Assessment of the multiple-dose pharmacokinetic interaction of lopinavir/ritonavir with nelfinavir. In: 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA, February 2003 [Abstract 536].
17. Corbett A, Eron J, Rezk N, Diebold M, Kashuba A. A triple protease inhibitor salvage regimen of amprenavir + saquinavir + ritonavir: steady state pharmacokinetics and initial RNA and CD4 response. In: XIVth International AIDS Conference. Barcelona, Spain, July 2002 [Abstract TuPeB4464].
18. Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir? AIDS 2002, 16:296-297.
19. Reynolds HE, Gibbons SE, Tija JF, Khoo SH, Back DJ. The pharmacokinetic interaction of lopinavir/ritonavir and amprenavir in clinical practice. In: XIVth International AIDS Conference. Barcelona, Spain, July 2002 [Abstract TuPeB4560].
20. Khanlou H, Graham E, Brill M, Farthing C. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS 2002, 16:797-798.
21. Harris M, McNabb K, Harrigan R, Alexander C, Press N, O'Shaughnessy M, et al. Dual boosted protease inhibitor regimens: preliminary results in rescue therapy. In: 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001 [Abstract 685].
22. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001, 15:1009-1118.
23. Mauss S, Scholten S, Wolf E, Berger F, Schmutz G, Jaeger H, et al. Does ritonavir 200 mg bid inhibit the interference of lopinavir with amprenavir plasma concentration in HIV-positive patients? In: 6th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2002 [Abstract 167].
24. Raguin G, Taburet AM, Chene G, Morand-Joubert L, Droz C, LeTiec C, et al. Pharmacokinetic parameters and virological response to the combination of lopinavir/ritonavir (LPV/r) and amprenavir (APV) in HIV-infected patients with multiple treatment failures: week-6 results of Puzzle 1-ANRS study. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA, February 2002 [Abstract 420-W].